Bemiparin as a Thromboprophylaxis After Gynaecological Surgeries
Launched by HAWLER MEDICAL UNIVERSITY · Jun 27, 2012
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
Deep vein thrombosis (DVT) and pulmonary embolism (PE), also referred to as venous thromboembolic events (VTE), are two major complications after gynaecological surgeries that can result in significant morbidity and mortality. The incidence of VTE after gynaecologic surgery varies depending on the method used for diagnosis. The rate of clinical DVT is estimated to be 3% after gynaecological surgery if no thromboprophylaxis was used. The rate of VTE assumed to decrease to 0.4% if Low molecular weight heparin was used as a thromboprophylaxis.
According to our knowledge there are no published...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • female undergoing Benign gynecological surgeries.
- • Having moderate,high and very high risk factors for venous thromboembolism.
- • No contraindications for the use of Heparin.
- Exclusion Criteria:
- • Having mild risk factors for thromboembolism.
- • Active vaginal bleeding.
- • Thrombocytopaenia.
- • any patient who is already on anticoagulant.
- • Sever renal or Liver diseases.
About Hawler Medical University
Hawler Medical University is a prominent academic institution dedicated to advancing medical education, research, and clinical practice in the Kurdistan Region of Iraq. As a clinical trial sponsor, the university prioritizes the integration of innovative research methodologies to enhance healthcare outcomes. Committed to ethical standards and scientific rigor, Hawler Medical University collaborates with a diverse network of healthcare professionals and researchers to conduct impactful clinical trials that address pressing health challenges. Through its initiatives, the university aims to contribute to the global body of medical knowledge while fostering a culture of inquiry and excellence in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Erbil City, Kurdistan Region, Iraq
Erbil, Kurdistan Region, Iraq
Patients applied
Trial Officials
Shahla K. Alalaf, M.D
Principal Investigator
Hawler Medical University
Ariana K. Jawad, C.A.B.OG
Study Chair
Hawler Ministry of Health
Rojan K. Jawad, Diploma
Study Chair
Hawler Medical University
Mahabad S. Ali, Diploma
Study Chair
Hawler Ministry of Health
Namir G. Al Tawil, Professor
Study Director
Hawler Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials